

Sartorius Group
Interim Report from January to March 2015

2015

Key Figures for the First Quarter of 2015

in millions of € unless otherwise specified

	Group			Bioprocess Solutions			Lab Products & Services		
	3-mo. 2015	3-mo. 2014	Δ in %	3-mo. 2015	3-mo. 2014	Δ in %	3-mo. 2015	3-mo. 2014	Δ in %
Order Intake and Sales									
Order intake	276.1	225.1	22.7	204.7	158.1	29.5	71.5	67.0	6.6
Sales revenue	258.1	203.1	27.0	186.0	137.7	35.1	72.1	65.4	10.2
- EMEA ¹⁾	124.5	107.1	16.3	86.0	70.0	22.9	38.5	37.1	3.8
- Americas ¹⁾	80.7	53.1	51.9	66.8	42.2	58.3	13.9	10.9	27.2
- Asia Pacific ¹⁾	52.9	42.9	23.1	33.2	25.5	29.9	19.7	17.4	13.0
Results									
EBITDA ²⁾	57.5	38.7	48.7	46.5	29.6	57.3	11.0	9.1	20.9
EBITDA margin ²⁾ in %	22.3	19.0		25.0	21.5		15.2	13.9	
Relevant net profit ³⁾	22.1	13.3	66.8						
Earnings per ordinary share ³⁾ in €	1.29	0.77	67.6						
Earnings per preference share ³⁾ in €	1.31	0.79	65.9						

¹⁾ Acc. to customers' location

²⁾ Underlying (adjusted for extraordinary items)

³⁾ Continuing operations after non-controlling interest, adjusted for extraordinary items as well as non-cash amortization, and based on a normalized financial result and corresponding tax effects.

Interim Management Report

- Substantial double-digit gains in order intake and sales revenue
- Positive currency effects support business development
- Significantly overproportionate increase in underlying EBITDA
- Forecast for the full year of 2015 raised

Group Business Development

Order Intake and Sales Revenue

After the Sartorius Group sold its Industrial Technologies Division with economic effect as of January 1, 2015, reporting of its business development is based on continuing operations, i.e., the divisions of Bioprocess Solutions and Lab Products & Services.

Moreover, Sartorius slightly changed the definition of its reporting by region. As a result, "Other Markets" formerly reported separately are now assigned to the regions defined as the Americas, EMEA¹⁾ and Asia | Pacific.

Order Intake and Sales Revenue

The Sartorius Group started off the year with significant double-digit gains in order intake, sales revenue and earnings. Group order intake thus rose 13.1 % in constant currencies (cc) from €225.1 million to €276.1 million (reported: +22.7 %). Consolidated sales revenue grew 17.2 % (cc) against weak prior-year comparables, from €203.1 million to €258.1 million (reported: +27.0 %).

The Bioprocess Solutions Division substantially increased its order intake by 18.3 % (cc) from €158.1 million to €204.7 million (reported: +29.5 %). Large equipment orders contributed to this surge besides the strong demand for single-use products. With respect to sales, Sartorius had expected above-average growth rates due to the low prior-year revenue base. Yet these gains that were driven by all product segments turned out to be higher than expected. Sales revenue for the Bioprocess Solutions Division thus jumped 23.4 % (cc) from €137.7 million to €186.0 million (reported: +35.1 %).

All regions contributed to the dynamic business performance of the Bioprocess Solutions Division, recording double-digit growth rates. The Americas region reported the highest growth momentum against a moderate year-earlier quarter, with an increase of around 32 % in sales revenue. In the EMEA and Asia | Pacific regions, sales revenue grew by around 21 % and 17 %, respectively. (All rates of change in constant currencies)

Bioprocess Solutions				
in millions of € unless otherwise specified	3-mo. 2015	3-mo. 2014	Δ in %	Δ in % const. fx
Order intake	204.7	158.1	29.5	18.3
Sales revenue	186.0	137.7	35.1	23.4
- EMEA ²⁾	86.0	70.0	22.9	20.5
- Americas ²⁾	66.8	42.2	58.3	32.3
- Asia Pacific ²⁾	33.2	25.5	29.9	16.6
EBITDA ³⁾	46.5	29.6	57.3	
EBITDA margin ³⁾ in %	25.0	21.5		

²⁾ Acc. to customers' location

³⁾ Underlying (adjusted for extraordinary items)

In the first three months of the current fiscal year, order intake for the Lab Products & Services Division rose against a strong Q1 2014 by 0.8 % (cc) to €71.5 million (reported: +6.6 %). The division's sales revenue increased 4.3 % to €72.1 million (reported: +10.2 %).

Sales growth in the Lab Products & Services Division was fueled by all regions. With sales up around 9 %, the Americas region contributed the highest gain. In the reporting period, sales revenue in the EMEA region likewise showed robust development, with sales up around 4 %. In the Asia | Pacific region, the market environment continued to stabilize in the reporting quarter. Accordingly, order intake was considerably above the previous year's level. Sales revenue in this region rose by around 2 % in the reporting year. (All rates of change in constant currencies)

Lab Products & Services				
in millions of € unless otherwise specified	3-mo. 2015	3-mo. 2014	Δ in %	Δ in % const. fx
Order intake	71.5	67.0	6.6	0.8
Sales revenue	72.1	65.4	10.2	4.3
- EMEA ²⁾	38.5	37.1	3.8	4.1
- Americas ²⁾	13.9	10.9	27.2	8.7
- Asia Pacific ²⁾	19.7	17.4	13.0	2.0
EBITDA ³⁾	11.0	9.1	20.9	
EBITDA margin ³⁾ in %	15.2	13.9		

²⁾ Acc. to customers' location

³⁾ Underlying (adjusted for extraordinary items)

¹⁾ EMEA = Europe | Middle East | Africa

Earnings Development

The Sartorius Group uses underlying EBITDA (earnings before interest, taxes, depreciation and amortization) as the key profitability indicator.

On the whole, the Sartorius Group markedly increased its underlying EBITDA in the first quarter against low year-earlier comparables, by 48.7 % from €38.7 million to €57.5 million. Driven by economies of scale and noticeably positive currency effects, its respective EBITDA margin reached 22.3 % relative to 19.0 % a year ago.

The Bioprocess Solutions Division boosted its underlying EBITDA by 57.3 % to €46.5 million. In addition to positive currency effects, economies of scale associated with strong sales growth especially contributed to this dynamic development of earnings. The division's EBITDA margin accordingly rose to 25.0 % from 21.5 % a year earlier. Underlying EBITDA for the Lab Products & Services Division increased, due to higher sales as well as currency effects, from €9.1 million to €11.0 million; its corresponding margin was 15.2 % relative to 13.9 % in the prior-year period.

First-quarter extraordinary items in the current fiscal year were -€1.8 million after -€1.2 million in the previous year.

Consolidated EBIT, including all extraordinary items, depreciation and amortization, was €42.4 million compared with €25.2 million a year ago. The Group's EBIT margin rose accordingly from 12.4 % a year earlier to 16.4 %.

The considerable change in the financial result (-€14.6 million against -€4.4 million in Q1 2014) is predominantly due to valuation effects related to foreign currency liabilities and hedges.

Net profit for the period was €55.4 million (Q1 2014: €15.1 million). This figure includes €35.9 million (Q1 2014: €0.5 million) related to the Industrial Technologies Division reported as a discontinued operation and reflects the gain on disposal of this business.

Net profit after non-controlling interest totaled €49.8 million, up from €11.0 million a year ago, with non-controlling interest accounting for €5.6 million (Q1 2014: €4.0 million.)

Relevant Net Profit

The relevant net profit attributable to the shareholders of Sartorius AG for its continuing operations amounted to €22.1 million (Q1 2014: €13.3 million¹⁾). This profit figure is calculated by adjusting for extraordinary items and eliminating non-cash amortization, and is based on the normalized financial result as well as the corresponding tax effects for each of these items. Underlying earnings per ordinary share were €1.29 (Q1 2014: €0.77¹⁾) and per preference share €1.31 (Q1 2014: €0.79¹⁾).

¹⁾ Restated

Assets and Financial Position

Cash Flow

In the first three months of the current fiscal year, the Sartorius Group reported a net cash flow from operating activities of €13.6 million relative to €20.2 million a year ago. The primarily sales-induced increase in funds tied up in net working capital especially influenced this figure. The discontinued operation accounted for €1.8 million in the first quarter of 2015 and - €1.2 million in the year-earlier period, respectively.

At - €20.5 million, net cash flow from investing activities was above the prior-year figure of - €18.7, as planned.

The sale of the Industrial Technologies Division in the reporting period resulted in a gross cash inflow of around €90 million. Overall, net cash flow from investing activities and acquisitions | divestitures was €52.6 million relative to - €18.7 million in the comparable reporting period.

Consolidated Statement of Financial Position

According to IFRS 5, the prior-year consolidated statement of financial position is not required to be restated with respect to disclosure of assets and liabilities of the discontinued operation. Accordingly, the following comparables include the assets and liabilities related to the Industrial Technologies Division.

The balance sheet total for the Sartorius Group slightly rose from €1,272.4 million at December 31, 2014, to €1,309.4 million as of the period ended March 31, 2015. The predominantly sales-induced increase in working capital and the rise in cash and cash equivalents were largely offset by the disposal of the Industrial Technologies Division with its assets amounting to €75.9 million.

Driven by earnings, equity substantially increased from €497.1 million to €574.6 million between December 31, 2014, and the reporting date. The equity ratio rose accordingly from 39.1 % to 43.9 % as of March 31, 2015.

Gross debt decreased from €392.1 million as of December 31, 2014, to €341.6 million as of March 31, 2015. Net debt at €269.7 million as of the reporting date was significantly below the figure of €335.6 million reported for the year ended December 31, 2014. The sale of the Industrial Technologies Division contributed substantially to this decrease.

The ratio of net debt to underlying EBITDA based on the past 12 months improved from 1.7 at the end of 2014 to 1.3 as of March 31, 2015.

Opportunity and Risk Report

The situation concerning opportunities and risks for the Sartorius Group has not materially changed since the publication of its 2014 Annual Report. This is why reference is made at this point to the detailed description of the opportunities and risks as well as the risk management system of the Sartorius Group on pages 56 et seq. and 68 et seq., respectively, in the 2014 Annual Report.

Forecast

Outlook for 2015

Based on positive first-quarter performance in fiscal 2015, management has raised its growth and earnings forecast for the full year of 2015. Assuming an overall stable economic environment, as well as excluding acquisitions, the company projects that sales will grow approximately 6 % to 9 % in constant currencies (previous guidance approx. 4 % to 7 %). The Group's underlying EBITDA margin based on constant currencies is expected to increase to around 22 % (previous guidance around 21.5 %).

For fiscal 2015, Sartorius continues to plan on investing around 10 % of sales revenue in projects that include the consolidation and extension of Group headquarters in Goettingen, Germany, which is scheduled to cover several years; expansion of production capacities; and the international rollout of its new ERP system.

Regarding the company's financial position, the Group maintains its expectations for year-end 2015 that if the targets previously mentioned are achieved, the ratio of net debt to underlying EBITDA will be below the previous year's level, without any potential acquisitions considered.

Based on excellent first-quarter performance by the Bioprocess Solutions Division, management now projects that the division's sales revenue will grow 8 % to 11 % in constant currencies (previous guidance: approx. 5 % to 8 %) and its underlying EBITDA margin will reach around 25 % on a constant currency basis (previous guidance: 24.5 %).

The company confirms its guidance for the Lab Products & Services Division: its currency-adjusted sales revenue is expected to increase by about 2 % to 5 % and its underlying EBITDA margin is anticipated to rise to around 15.5 % in constant currencies.

Report on Material Events

Sartorius acquired BioOutsource Ltd. through its Sartorius Stedim Biotech subgroup on April 17, 2015. Headquartered in Glasgow, UK, BioOutsource specializes in contract testing services in bioanalytics and biosafety. With around 85 employees, the company currently generates sales of approximately €9 million.

Interim Financial Statements

Statement of Profit or Loss

	3-month 2015 € in mn	3-month 2014 € in mn
Sales revenue	258.1	203.1
Cost of sales	-132.1	-105.1
Gross profit on sales	126.0	98.0
Selling and distribution costs	-54.0	-48.7
Research and development costs	-14.1	-13.4
General administrative expenses	-15.6	-14.1
Other operating income and expenses ¹⁾	0.2	3.4
Earnings before interest and taxes (EBIT)	42.4	25.2
Financial income	4.7	0.2
Financial expenses	-19.3	-4.6
Financial result	-14.6	-4.4
Profit before tax	27.8	20.8
Income taxes	-8.3	-6.3
Profit after tax from continuing operations	19.5	14.6
Profit after tax from discontinued operation	35.9	0.5
Net profit for the period	55.4	15.1
Attributable to:		
Shareholders of Sartorius AG	49.8	11.0
Non-controlling interest	5.6	4.0
Earnings per ordinary share (€) (basic = diluted)	2.91	0.64
Of which from continuing operations	0.80	0.61
Of which from discontinued operation	2.11	0.03
Earnings per preference share (€) (basic = diluted)	2.93	0.66
Of which from continuing operations	0.82	0.63
Of which from discontinued operation	2.11	0.03

¹⁾ The item "Other operating income and expenses" includes extraordinary expenses of €1.8 million for the three-month period of 2015 (3-mo. 2014: €1.2 million).

Statement of Comprehensive Income

	3-month 2015 € in mn	3-month 2014 € in mn
Net profit for the period	55.4	15.1
Cash flow hedges	-10.6	-2.4
Income tax on cash flow hedges	3.2	0.7
Net investment in a foreign operation	-6.1	0.0
Income tax on net investment in a foreign operation	1.9	0.0
Currency translation differences	33.4	0.0
Items that will be reclassified in the profit or loss statement, net of tax	21.8	-1.6
Actuarial gains losses on defined benefit obligations	-0.1	0.0
Income tax on items that will not be reclassified in the profit or loss statement	0.0	0.0
Items that will not be reclassified in the profit or loss statement, net of tax	-0.1	0.0
Other comprehensive result after tax	21.7	-1.6
Total comprehensive income	77.1	13.5
Attributable to:		
Shareholders of Sartorius AG	66.4	9.6
Non-controlling interest	10.6	3.9

Statement of Financial Position

	March 31, 2015	December 31, 2014
	€ in mn	€ in mn
Assets		
Non-current assets		
Goodwill	385.5	382.4
Other intangible assets	171.0	168.6
Property, plant and equipment	268.6	254.9
Financial assets	7.9	7.7
Other assets	1.0	0.7
Deferred tax assets	23.1	21.9
	857.2	836.4
Current assets		
Inventories	170.7	145.9
Trade receivables	165.4	140.4
Other financial assets	13.4	11.8
Current tax assets	17.0	11.0
Other assets	13.8	10.6
Cash and cash equivalents	71.9	40.6
Assets held for sale	0.0	75.9
	452.2	436.1
Total assets	1,309.4	1,272.4
	March 31, 2015	December 31, 2014
	€ in mn	€ in mn
Equity and liabilities		
Equity		
Equity attributable to Sartorius AG shareholders	465.0	398.0
Issued capital	17.0	17.0
Capital reserves	87.4	87.0
Other reserves and retained earnings	360.6	293.9
Non-controlling interest	109.6	99.1
	574.6	497.1
Non-current liabilities		
Pension provisions	61.7	61.2
Other provisions	7.4	7.3
Loans and borrowings	313.9	359.9
Finance lease liabilities	18.9	18.8
Other financial liabilities	64.0	49.6
Deferred tax liabilities	26.2	29.8
	492.2	526.5
Current liabilities		
Provisions	9.1	8.9
Trade payables	104.1	90.5
Loans and borrowings	6.5	11.1
Finance lease liabilities	2.3	2.3
Other financial liabilities	83.6	78.8
Current tax liabilities	12.7	11.1
Other liabilities	24.4	15.7
Liabilities in connection with assets held for sale	0.0	30.6
	242.6	248.9
Total equity and liabilities	1,309.4	1,272.4

Statement of Cash Flows

	3-month 2015 € in mn	3-month 2014 € in mn
Profit before tax	64.4	21.6
Financial result	14.3	4.5
Depreciation amortization of intangible and tangible assets	13.2	12.7
Increase decrease in provisions	-6.6	-1.4
Gains losses from the disposal of fixed assets	-35.1	0.0
Income taxes paid	-12.3	-6.5
Other non-cash items	-1.8	0.0
Gross cash flows from operating activities	36.1	30.8
Increase decrease in receivables and other assets	-16.8	3.4
Increase decrease in inventories	-18.9	-10.5
Increase decrease in liabilities (without loans and borrowings)	13.1	-3.6
Net cash flow from operating activities	13.6	20.2
Net cash flow from operating activities - continuing operations	11.8	21.4
Net cash flow from operating activities - discontinued operation	1.8	-1.2
Capital expenditures	-21.2	-18.8
Proceeds from the disposal of fixed assets	0.8	0.7
Other payments	-0.1	-0.6
Net cash flow from investing activities	-20.5	-18.7
Proceeds from the disposal of consolidated subsidiaries, net of cash disposed	73.1	0.0
Net cash flow from investing activities, acquisitions and disposals	52.6	-18.7
Net cash flow from investing activities - continuing operations	-20.3	-17.6
Net cash flow from investing activities - discontinued operation	72.9	-1.1
Interest received	0.1	0.1
Interest paid and other financial charges	-2.9	-3.1
Dividends paid to:		
Shareholders of Sartorius AG	0.0	0.0
Non-controlling interest	0.0	0.0
Gross cash flows from financing activities	-2.8	-3.0
Changes in non-controlling interest	0.1	0.0
Loans and borrowings repaid raised	-51.2	-6.6
Net cash flow from financing activities	-54.0	-9.6
Net cash flow from financing activities - continuing operations	-54.0	-9.6
Net cash flow from financing activities - discontinued operation	0.0	0.0
Net increase decrease in cash and cash equivalents	12.2	-8.2
Cash and cash equivalents at the beginning of the period	56.4	51.9
Net effect of currency translation on cash and cash equivalents	3.3	-0.2
Cash and cash equivalents at the end of the period	71.9	43.5

Statement of Changes in Equity

€ in millions	Issued capital	Capital reserves	Hedging reserves	Pension reserves	Earnings reserves and retained profits	Difference resulting from currency translation	Equity attributable to Sartorius AG shareholders	Non-controlling interest	Total equity
Balance at Jan. 1, 2014	17.0	87.0	-1.4	-9.9	284.4	-9.5	367.6	82.6	450.3
Net profit for the period			0.0	0.0	11.0	0.0	11.0	4.0	15.1
Other comprehensive result after tax			-1.4	0.0	0.0	-0.1	-1.5	-0.1	-1.6
Total comprehensive income			-1.4	0.0	11.0	-0.1	9.6	3.9	13.5
Dividends					0.0		0.0	0.0	0.0
Other changes in equity					-0.1		-0.1	0.0	-0.1
Balance at March 31, 2014	17.0	87.0	-2.8	-9.9	295.4	-9.6	377.1	86.5	463.7

€ in millions	Issued capital	Capital reserves	Hedging reserves	Pension reserves	Earnings reserves and retained profits	Difference resulting from currency translation	Equity attributable to Sartorius AG shareholders	Non-controlling interest	Total equity
Balance at Jan. 1, 2015	17.0	87.0	-2.2	-19.4	307.6	7.8	398.0	99.1	497.1
Net profit for the period			0.0	0.0	49.8	0.0	49.8	5.6	55.4
Other comprehensive result after tax			-6.0	2.4	-5.6	25.9	16.6	5.0	21.7
Total comprehensive income			-6.0	2.4	44.2	25.9	66.4	10.6	77.1
Aktienbasierte Vergütung		0.3			0.0		0.3	0.0	0.3
Dividends					0.0		0.0	0.0	0.0
Other changes in equity					0.3		0.3	-0.2	0.1
Balance at March 31, 2015	17.0	87.4	-8.2	-16.9	352.0	33.7	465.0	109.6	574.6

Segment Reports

€ in millions	Sales revenue		Underlying EBITDA	
	3-mo. 2015	3-mo. 2014	3-mo. 2015	3-mo. 2014
Bioprocess Solutions	186.0	137.7	46.5	29.6
Lab Products & Services	72.1	65.4	11.0	9.1
Total continuing operations	258.1	203.1	57.5	38.7
Reconciliation to the profit before tax				
Depreciation and amortization			-13.2	-12.2
Extraordinary items			-1.8	-1.2
Earnings before interest and taxes (EBIT)			42.4	25.2
Financial result			-14.6	-4.4
Profit before tax from continuing operations			27.8	20.8

Geographical Information

In fiscal 2015, the presentation of the regions was slightly changed. As a result, the countries formerly allocated to "Other Markets" are now assigned to the regions defined as EMEA (Europe, the Middle East and Africa), the Americas and Asia | Pacific.

€ in millions	Sales revenue	
	3-mo. 2015	3-mo. 2014
EMEA	124.5	107.1
Americas	80.7	53.1
Asia Pacific	52.9	42.9
Group	258.1	203.1

Notes to the Interim Financial Statements

1. Significant Accounting Policies

The consolidated annual financial statements of Sartorius AG for the period ended December 31, 2014, were prepared in accordance with the accounting standards of the International Accounting Standards Board (IASB) – the International Financial Reporting Standards (IFRS) as they are to be applied in the EU. In the present interim financial statements that were prepared in conformance with the requirements of IAS 34 "Interim financial reporting," basically the same accounting and measurement principles were applied on which the past consolidated financial statements of fiscal 2014 were based.

Furthermore, all interpretations of the International Financial Reporting Standards Interpretations Committee (IFRS IC) to be applied effective March 31, 2015, were observed. An explanation of the individual accounting and measurement principles applied is given in the Notes to the Financial Statements of the Group for the year ended December 31, 2014.

2. Accounting Rules Applied for the First Time in the Current Fiscal Year

The following new accounting rules were applicable for the first time to the present interim financial statements and had no impact on the presentation of the company's net worth, financial position and profitability or earnings per share:

- Annual improvements to IFRS – cycle 2011– 2013
- IFRIC 21: Levies

3. Acquisition of AllPure Technologies LLC

On April 25, 2014, Sartorius through its subgroup Sartorius Stedim Biotech acquired 50.01% in the U.S. startup AllPure Technologies LLC at a price of 6 million U.S. dollars.

The shares in Allpure remaining with the former owners will also be transferred to Sartorius by 2022 at the latest. The exact time of this acquisition, as well as the purchase price, depend on the future business performance of the entity purchased. The corresponding liability is disclosed in the financial liabilities as the present value of the expected future payments of €7.1 million. This liability was initially recognized in the retained earnings according to IAS 32.23; its subse-

quent measurement will be recognized through profit or loss in the financial result.

The preliminary purchase price allocation was as follows:

	Preliminary purchase price allocation € in mn
Intangible and tangible assets	2.1
Inventories	0.5
Trade receivables and other assets	0.3
Cash and cash equivalents	0.0
Provisions and liabilities	-0.5
Net assets acquired	2.4
- of which 50.01%	1.2
Purchase price	4.3
Goodwill	3.1
Non-controlling interest	1.2

The purchase price allocation will be finalized in the second quarter of 2015.

4. Sale of the Industrial Technologies Division

On December 19, 2014, Sartorius AG signed a contract to sell the Industrial Technologies Division (Intec) to the Japanese Minebea group and its partner, the Development Bank of Japan.

For the Sartorius Group, the sale of this entity is an important milestone as part of the company's strategy to concentrate on its two core divisions Bioprocess Solutions und Lab Products & Services. These divisions offer higher growth and earnings potential. However, to unlock this potential, a high degree of focus and further major investments are necessary at the same time. The proceeds from the sale of the Intec Division are strengthening the company's financial potential for this further expansion of Sartorius' core businesses.

The sale of the Intec Division has resulted in the application of IFRS 5, "Non-current assets held for sale and discontinued operations," and thus in the disclosure of the Intec Division as a discontinued operation. Therefore, the expenses and income of this operation, including the gain on disposal, are disclosed in the item "Profit after tax from discontinued operation." The disclosures in this report accordingly refer to the continuing operations, unless otherwise specified. The

prior-year disclosures in the statement of profit or loss were correspondingly adjusted.

Following legal completion of the sales transaction, the Industrial Technologies Division was deconsolidated on February 1, 2015. The gain on disposal is as follows:

	€ in mn
Sale price (paid in cash)	90.3
Net assets disposed	-55.2
Gain on disposal before tax	35.1

5. Explanatory Notes to the Segment Reports

The following table restates the underlying EBITDA of the segments with respect to the Group's profit before tax:

€ in millions	3-mo. 2015	3-mo. 2014
Underlying EBITDA of the segments	57.5	38.7
Depreciation and amortization	-13.2	-12.2
Extraordinary items	-1.8	-1.2
EBIT	42.4	25.2
Financial result	-14.6	-4.4
Profit before tax	27.8	20.8

6. Financial Instruments

The following table compares the carrying amounts of financial assets and liabilities for each category of financial instruments with their fair values and reconciles these with the corresponding items on the statement of financial position.

€ in millions	Category acc. to IAS 39	March 31, 2015 Carrying amount	March 31, 2015 Fair value	Dec. 31, 2014 Carrying amount	Dec. 31, 2014 Fair value
Financial assets	Available for sale	6.2	6.2	6.1	6.1
Financial assets	Loans and receivables	1.7	1.7	1.7	1.7
Financial assets (non-current)		7.9	7.9	7.7	7.7
Trade receivables	Loans and receivables	165.4	165.4	140.4	140.4
Receivables and other assets	Loans and receivables	13.3	13.3	11.6	11.6
Derivative financial instruments	Held for trading	0.0	0.0	0.0	0.0
Derivative financial instruments	Hedging instruments	0.2	0.2	0.1	0.1
Other financial assets (current)		13.5	13.5	11.8	11.8
Cash and cash equivalents	Loans and receivables	71.9	71.9	40.6	40.6
Loans and borrowings	Financial liabilities at cost	320.4	330.0	371.0	380.9
Finance lease liabilities	IFRS 7	21.2	25.8	21.1	24.2
Trade payables	Financial liabilities at cost	64.0	64.0	56.6	56.6
Trade payables	Not IFRS 7	40.1	40.1	33.9	33.9
Trade payables		104.1	104.1	90.5	90.5
Derivative financial instruments	Held for trading	10.4	10.4	9.0	9.0
Derivative financial instruments	Hedging instruments	15.0	15.0	4.4	4.4
Other financial liabilities	Financial liabilities at cost	85.3	88.6	77.1	80.2
Other financial liabilities	Not IFRS 7	37.0	37.0	38.0	38.0
Other financial liabilities		147.7	150.9	128.4	131.5

The fair values of the financial instruments were determined on the basis of the market information available on the reporting date and are to be allocated to one of the three levels of the fair value hierarchy in accordance with IFRS 13.

Level 1 financial instruments are calculated on the basis of prices quoted on active markets for identical assets and liabilities. In Level 2, financial instruments are calculated on the basis of input factors, which are derivable from observable market data or on the basis of market prices for similar instruments. Level 3 financial instruments are calculated on the basis of input factors that cannot be derived from observable market data.

For the equity investments measured at acquisition cost (financial assets), it is not possible to determine fair values reliably due to the absence of active markets. This applies mainly to shares in non-consolidated subsidiaries. It is assumed that the carrying amounts correspond to the fair values as of the reporting date.

The financial instruments to be recognized at fair value on the reporting date are exclusively derivatives in the form of forward contracts and interest rate swaps. They were measured on the basis of their quoted exchange rates and market yield curves, taking counterparty risks into account (Level 2).

The fair values to be disclosed for financial liabilities recognized at amortized cost, especially liabilities to banks and those related to note loans ("Schuldscheindarlehen"), as well as finance lease liabilities, were measured on the basis of the market interest rate curve according to the zero coupon method, taking the current indicative credit spreads into account (Level 3).

The Allpure liability is required to be disclosed in the amount of the present value of the expected purchase price payments for the non-controlling interest in this company. This present value is to be derived from the expected AllPure sales revenues as of the exercise date

and from the risk-adjusted discount rate presented above.

The fair values of the remaining financial assets and liabilities to be disclosed approximate the carrying amounts on account of their predominantly short-term maturity.

7. Other Disclosures

No dividends were paid in the reporting period.

Independent, certified auditors have not performed an audit review of this consolidated three-month report.

8. Material Events After the Reporting Date

Sartorius through its subgroup Sartorius Stedim Biotech acquired the Scottish company BioOutsource Ltd. on April 17, 2015. Headquartered in Glasgow, UK, BioOutsource offers bioanalytical contract testing services for the biopharmaceutical industry. BioOutsource services are part of the core processes of the Sartorius Group's customers and therefore extend this Group's current service offering. With 85 employees, BioOutsource earned sales revenue of around €9 million in the last twelve months. The purchase price to be paid in cash is around €30 million.

Contacts

Sartorius AG
Weender Landstrasse 94–108
37075 Goettingen, Germany

Phone +49.551.308.0
Fax +49.551.308.3289
www.sartorius.com

Group Corporate Communications

Petra Kirchhoff
Vice President
Phone +49.551.308.1686
petra.kirchhoff@sartorius.com

Investor Relations

Andreas Theisen
Director
Phone +49.551.308.1668
andreas.theisen@sartorius.com

Financial Schedule

May 20 | 21, 2015

Commerzbank Midcap Conference in New York | Boston, USA

June 17, 2015

DB Access Conference in Berlin, Germany

July 22, 2015

Publication of first-half figures for 2015

October 20, 2015

Publication of nine-month figures for 2015

November 23, 2015

German Equity Forum in Frankfurt Main, Germany

January 2016

Publication of the preliminary results for fiscal 2015

This is a translation of the original German-language three-month Group interim financial report (January to March 2015) entitled "Sartorius Konzern Zwischenbericht – Januar bis März 2015." Sartorius AG shall not assume any liability for the correctness of this translation. The original German interim report is the legally binding version. Furthermore, Sartorius AG reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Forward-looking Statements Contain Risks

This Sartorius Group Interim Report for the period of January to the end of March 2015 contains various statements concerning the Sartorius Group's future performance. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually apply. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements.

Throughout the entire report, differences may be apparent as a result of rounding during addition.